US04016X1019 - ADR
477.84 +0.05 (+0.01%)
ARGENX SE - ADR
NASDAQ:ARGX (9/28/2023, 10:10:00 AM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 843 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
ARGENX SE - ADR
Amsterdam NOORD-HOLLAND 4811 AH
CEO: Tim Van Hauwermeiren
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.
The company may have best-in-class autoimmune disease therapy under its roof.
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.
OmniAb shares rise while argenx shares decline after Immunovant posts positive early-stage data for its autoimmune drug candidate, IMVT-1402. Read more here.
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.
Here you can normally see the latest stock twits on ARGX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.